Scarica l'app Stockscreener
1.06
9.55%
0.0924
Dyadic International Inc De Borsa (DYAI) Ultime notizie
Dyadic International stock reflects a thin catalyst day. Focus stays on its enzyme platform. - AD HOC NEWS
DYAIDyadic International Inc, DE Forecast, Target Price - Finviz
Enzyme Complex Digestive Market Forecast 2026-2035: Growth Driven by Feed Efficiency and Antibiotic ReductionNews and Statistics - IndexBox
Dyadic Shareholders Approve Reverse Split and Governance Proposals - TipRanks
An Interview with the President & COO: How Dyadic is Commercializing Its Protein Platform Across Multi-Billion-Dollar Markets - TradingView
Dyadic Faces Nasdaq Delisting Review After Compliance Failures - TipRanks
World Enzyme-Based Waste DegradationMarket Analysis, Forecast, Size, Trends and Insights - IndexBox
Dyadic Showcases C1 Platform Amid Ebola Preparedness Surge - TipRanks
World Amyloglucosidase EnzymeMarket Analysis, Forecast, Size, Trends and Insights - IndexBox
De-Inking Enzymes Market is Booming Worldwide | Major Giants Megazyme, BASF SE, DuPont - openPR.com
Enzyme Stabilizer Market Trends Support A 6.7% CAGR Outlook Through The Forecast Period - openPR.com
Analysts Have Conflicting Sentiments on These Consumer Goods Companies: BioHarvest Sciences (BHST) and Brown Forman A (BF.A) - The Globe and Mail
Dyadic Under $1 as Investors Eye June Vote - Bez Kabli
Analysts Offer Insights on Healthcare Companies: Repligen (RGEN), Vaxcyte (PCVX) and BeOne Medicines (ONC) - The Globe and Mail
Dyadic International Launches Recombinant Human Albumin and Bovine Chymosin - asatunews.co.id
Analysts Offer Insights on Industrial Goods Companies: DroneShield Limited (OtherDRSHF), CryoPort (CYRX) and Deere (DE) - The Globe and Mail
Dyadic International (DYAI) Surges 13.8% – Key Levels in FocusETF AUM Growth - newsline.com
Dyadic and Scripps Research Partner to Accelerate Hantavirus Antibody and Vaccine Development Using C1 Biologic Platform - Minichart
Skyline Corporate Communications Group, LLC Announces Dyadic Applied BioSolutions to Deliver a Live Presentation at the Skyline Signature Series™ on Wednesday, May 27 at 12:00 PM ET - GlobeNewswire Inc.
Skyline Corporate Communications Group, LLC Announces - GlobeNewswire
Dyadic International’s Earnings Call Shows Early Momentum - The Globe and Mail
Dyadic International Earnings Call Highlights Early Momentum - TipRanks
Earnings call transcript: Dyadic’s Q1 2026 revenue surges 182% despite EPS miss By Investing.com - Investing.com Australia
Earnings call transcript: Dyadic’s Q1 2026 revenue surges 182% despite EPS miss - Investing.com
Japan’s First LNG Shipment via Hormuz Since Strait’s De Facto Closure Marks Energy Security MilestoneAnalyst Coverage Count - The Legal Advocate
Dyadic International stock (US26746E1055): Shares climb after recent momentum - AD HOC NEWS
Dyadic International, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Food Enzymes Market Size, Share, Analysis & Trends, 2034 - Market Data Forecast
Earnings call transcript: Dyadic International Q1 2026 revenue beats forecast, stock dips - Investing.com India
Earnings call transcript: Dyadic International Q1 2026 revenue beats forecast, stock dips By Investing.com - Investing.com India
Transcript: Dyadic International Q1 2026 Earnings Conference Call - Benzinga
Dyadic International (NASDAQ: DYAI) grows Q1 2026 revenue but flags going-concern risks - Stock Titan
Specialty Enzymes Market Overview, Emerging Trends, and Key Player Analysis - openPR.com
Analysis of Segments and Major Growth Areas in the Protein Hydrolysis Enzymes Market - openPR.com
Unusual VolumeStock ScreenerNews - Finviz
Biogen Inc. (BIIB)Dual Wall Street Upgrades Signal Bullish Pipeline Catalyst UpsideAnalyst Coverage Count - newsline.com
Dyadic International stock (US26746E1055): Is its biotech platform strong enough to unlock new upsid - AD HOC NEWS
Dyadic International Stock: Biotechnology Innovator Focused on C1 Platform Amid Earnings Challenges - AD HOC NEWS
Dyadic International Earnings Call Highlights Commercial Pivot - TipRanks
Dyadic International, Inc.'s (NASDAQ:DYAI) Path To Profitability - simplywall.st
Dyadic International Q4 2025 Earnings Call Transcript - MarketBeat
Dyadic Applied BioSolutions Reports 2025 Financial Results, Commercial Launches, and Strategic Partnerships in Animal-Free Protein Production 12346 - Minichart
Dyadic Applied BioSolutions: Innovative Microbial Protein Production Platforms for Life Sciences, Food, and Industrial Markets - Minichart
Dyadic International Inc (DYAI) Q4 2025 Earnings Call Highlights: Navigating Transition with ... By GuruFocus - ca.investing.com
Dyadic International’s ability to sustain operations for the next year and avoid significant dilution depends on the effectiveness of its shift toward commercial strategies - Bitget
Dyadic (DYAI) Q4 2025 Earnings Call Transcript - theglobeandmail.com
Earnings call transcript: Dyadic Q4 2025 reveals revenue decline, stock up 3.32% - Investing.com Australia
Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress - Yahoo Finance Singapore
Dyadic (NASDAQ: DYAI) posts lower 2025 revenue and wider annual net loss - Stock Titan
Dyadic International, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
EXCLUSIVE: Co-Diagnostics Expands South Asia Reach, Targets $13 Billion Market Opportunity - AOL.com
Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices - GlobeNewswire
Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026 - The Manila Times
Dyadic to detail full-year 2025 results in March 25 investor call - Stock Titan
Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th - GlobeNewswire
Decliners Report: Can Dyadic International Inc outperform under higher oil pricesWeekly Market Outlook & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Dyadic International Establishes At-the-Market Equity Offering Program - The Globe and Mail
Dyadic and Fermbox Bio Launch First Product Under Expanded - GlobeNewswire
Dyadic Applied BioSolutions and Inzymes ApS Announce - GlobeNewswire
Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone - Yahoo Finance
Dyadic's Strategic Pivot: From Platform to Product - AD HOC NEWS
1.17%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):